Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis

被引：15

作者：

Ghez, David ^{[1
]}

Micol, Jean-Baptiste ^{[1
]}

Pasquier, Florence ^{[1
]}

Auger, Nathalie ^{[2
]}

Saada, Veronique ^{[3
]}

Spentchian, Marc ^{[4
]}

Ianotto, Jean-Christophe ^{[5
]}

Bourhis, Jean-Henri ^{[1
]}

Bennaceur-Griscelli, Anelyse ^{[6
]}

Terre, Christine ^{[4
]}

Castaigne, Sylvie ^{[7
]}

Rigaudeau, Sophie ^{[7
]}

Rousselot, Philippe ^{[7
]}

de Botton, Stephane ^{[1
]}

机构：

[1] Inst Gustave Roussy, Serv Hematol, F-94805 Villejuif, France

[2] Inst Gustave Roussy, Lab Cytogenet, F-94805 Villejuif, France

[3] Inst Gustave Roussy, Serv Hematol Biol, F-94805 Villejuif, France

[4] Hop Andre Mignot, Serv Biol Med, F-78157 Le Chesnay, France

[5] Univ Morvan, Ctr Hosp, Serv Hematol, F-29609 Brest, France

[6] Inst Gustave Roussy, Mol Biol Lab, F-94805 Villejuif, France

[7] Hop Andre Mignot, Serv Hematol, F-78157 Le Chesnay, France

来源：

EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷 / 17期

关键词：

Chronic myelogenous leukaemia; Blast phase; Tyrosine kinase inhibitors; IMATINIB MESYLATE; STEM-CELLS; FOLLOW-UP; PHASE-II; THERAPY; DECITABINE; METHYLATION; CYTARABINE; DASATINIB; RESISTANT;

D O I：

10.1016/j.ejca.2013.07.147

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Even in the tyrosine kinase inhibitors era, the prognosis of patients with chronic myeloid leukaemia in myeloid blast crisis remains dismal with few patients surviving longer than 6 months. Here we report the cases of 5 patients treated with the combination of 5-azacytidine and tyrosine kinase inhibitors for myeloid blast crisis CML. All patients achieved a complete haematological response including two with a complete cytogenetic and major molecular response. Two patients underwent an allogeneic stem cell transplantation. One died from relapse 34 months from diagnosis. The second is alive and free from disease at 11 months from diagnosis. The other 3 patients are still in complete haematological response after 15, 24 and 33 months of follow-up. These results suggest that the combination has a significant activity in myeloid blast crisis and may increase survival. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：3666 / 3670

页数：5

共 50 条

[21] Molecular targets to guide tyrosine kinase inhibitor therapy in chronic myeloid leukaemia
Cotter, C.
Orfali, N.
Fadalla, K.
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 136 - 136
[22] Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemia
Lindstrom, H. Jonathan G.
de Wijn, Astrid S.
Friedman, Ran
BMC CANCER, 2019, 19 (1)
[23] Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemia
H. Jonathan G. Lindström
Astrid S. de Wijn
Ran Friedman
BMC Cancer, 19
[24] Molecular profiling and targeted inhibitor therapy in atypical chronic myeloid leukaemia in blast crisis
Langabeer, Stephen E.
Comerford, Claire M.
Quinn, John
Murphy, Philip T.
JOURNAL OF CLINICAL PATHOLOGY, 2017, 70 (12) : 1089 - 1089
[25] Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors
Lipton, J. H.
Bryden, P.
Sidhu, M. K.
Huang, H.
McGarry, L. J.
Lustgarten, S.
Mealing, S.
Woods, B.
Whelan, J.
Hawkins, N.
LEUKEMIA RESEARCH, 2015, 39 (01) : 58 - 64
[26] Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)
Elisabetta Abruzzese
Massimo Breccia
Roberto Latagliata
BioDrugs, 2014, 28 : 17 - 26
[27] The impact of second generation tyrosine kinase inhibitors on the outcome of allogeneic stem cell transplantation for chronic myeloid leukaemia
Latif, A.
Parker, A.
McQuaker, G.
Clark, A.
Copland, M.
BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 : 23 - 24
[28] Acneiform eruptions caused by various second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
Jung, Y. S.
Kim, M.
Lee, J. H.
Kim, D. W.
Park, H. J.
BRITISH JOURNAL OF DERMATOLOGY, 2016, 174 (02) : 456 - 458
[29] Use of second generation tyrosine kinase inhibitors prior to allogeneic stem cell transplantation in chronic myeloid leukaemia
Olavarria, E.
Schleuning, M.
Chalandon, Y.
Onida, F.
Radujkovic, A.
Robin, M.
Kroeger, N.
BONE MARROW TRANSPLANTATION, 2013, 48 : S35 - S36
[30] Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)
Abruzzese, Elisabetta
Breccia, Massimo
Latagliata, Roberto
BIODRUGS, 2014, 28 (01) : 17 - 26

← 1 2 3 4 5 →